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At the conclusion of this session, the participant  
will be able to: 
 
 State the numbers of travelers and persons under investigation for 
Ebola in the US from August 2014-March 2015 
 Discuss the most common diagnoses for persons under 
investigation for Ebola 
 Describe the importance for appropriate evaluation of persons 
under investigation for Ebola in assessment hospitals 
 Compare and contrast different options for evaluation of persons 
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Disclaimer 
The views and opinions in this 
presentation are those of the authors and 
not necessarily those of the Centers for 
Disease Control and Prevention (CDC) / 
Agency for Toxic Substances and 
Disease Registry (ATSDR) 
Overview 
 Introduction: role of Clinical Inquiries Team  
 Background: returning U.S. travelers 
 Geographic distribution of inquiries and 
persons under investigation (PUIs) 
 Common diagnoses among PUIs 
 Case studies 
 Emory: outpatient management of PUIs 





Tested PUIs 117 
PUIs 272 
Travelers getting evaluation 
reported to CDC 
Travelers with symptoms needing 
evaluation 
Travelers reporting symptoms 
Travelers with symptoms 
Monitored travelers from affected countries 
All travelers from affected countries  
Source: CDC Domestic Clinical Inquiries Team  
Number of persons traveling, monitored, and reported 
to CDC as PUIs with concerns about Ebola - United 
States, 2014-15 
Layered Lines of Defense against of Ebola 
Layered Lines of Defense against Ebola 
Travelers coming from 
countries with 
widespread Ebola 
transmission fly into 
one of five US airports 
(New York JFK, 
Newark, Washington-
Dulles, Chicago 
O’Hare, and Atlanta). 
 
Travelers are screened 
for symptoms and 
potential exposures 








screened before getting 
on their flight. 
 
Symptomatic or 
exposed travelers are 





All aircraft arriving in the 
United States are 
required to report deaths 
onboard and travelers 
with certain 
signs/symptoms of 









Referred  to CDC 









11,361 1,244 (11%) 20 (<0.2%) 0* 
* One traveler identified as a case after developing initial symptoms 4 days after arrival 
Pyramid 
Number of persons traveling, monitored, and reported 
to CDC as PUIs with concerns about Ebola -- United 
States, 2014-15 
Source: CDC Domestic Clinical Inquiries Team  
Confirmed 
Ebola 0 
Tested PUIs 117 
PUIs 272 
Travelers getting evaluation 
reported to CDC 
Travelers with symptoms needing 
evaluation 
Travelers reporting symptoms 
Travelers with symptoms 
Monitored travelers from affected countries 
All travelers from affected countries  
Travelers monitored in the U.S.  
March 16, 2015 – March 22, 2015 
 1,989 persons in active or direct active monitoring  
 73 some- or high-risk at any time during the reporting period  
 29 states with some- or high-risk persons under monitoring 
 99.9% of travelers were contacted for monitoring 







Tested PUIs 117 
PUIs 272 
Travelers getting evaluation 
reported to CDC - inquiries 
Travelers with symptoms needing 
evaluation 
Travelers reporting symptoms 
Travelers with symptoms 
Monitored travelers from affected countries 
All travelers from affected countries  
Source: CDC Domestic Clinical Inquiries Team  
Number of persons traveling, monitored, and reported 
to CDC as PUIs with concerns about Ebola -- United 
States, 2014-15 
Clinical Inquiries Team  
 Address inquiries about evaluation of 
travelers who may be persons under 
investigation (PUIs) 
 Document inquiries and PUI management 
 Communicate to HHS, other Federal 
partners, state and local health departments 
Domestic Clinical Inquiries (n=982) and Number of People 
Tested (n=117), by State, 9 July 2014-29 March 2015 
*Inquiries from outside US = 11 (Tested 2) 
Ebola Response Update 30 March 2015  
*Inquiries from DC = 32 
(Tested 3) 

























































N = number tested 
for Ebola
30 March 2015 
TX 1  
TX 2  












Domestic Clinical Inquiries by epi week, 
Testing through March 28, 2015 
Top five diagnoses among PUIs reported to CDC* 
December 1, 2014 – March 24, 2015 
n=110 
Diagnosis N=110 % 
1  Gastroenteritis 36 33 
2  Upper respiratory infection 19 17 
3  Influenza 18 16 
4  Malaria 10   9 
5  Unknown/other   7   6 
* may not include all PUIs in the U.S. 
Case Study #1 
Presentation 
 4-year-old arrived from Liberia  
 Classified as low but not zero risk, no known 
Ebola exposure, started active monitoring 
 Developed fever 101.7°F on day 15, no other 
symptoms, family well 
 Evaluation recommended on day 16, went to 
Hospital A 






Case Study #1 
Test Results and Outcomes  
 Rapid test:  P. falciparum + and P. vivax + 
 Hct 19, plts 42k, Tbili 3.5 
 Hospital A uncomfortable treating child PUI 
despite alternative diagnosis of malaria 
 Transferred by EMTs in full PPE to Hospital B 
late on day 17 
 Slow clinical improvement, delay in malaria 
treatment 
 Ebola testing negative >72 hours after 







Case study #2 - Media 
 Traveler arrived from Guinea 
 Monitoring initiated by local  
    health department 
 Traveler reported 102°F to LHD on day 5, early am 
 LDH called local hospital to initiate evaluation, then 
notified state 
 Hospital called EMS to arrange transport 
 EMS radio:  “Possible Ebola patient being transported…” 
 Reporter monitoring EMS radio filed press report 
 DHHS, CDC, State Health Department unaware of PUI 
getting evaluation 
 
Case study #3 
Presentation  
 47-year-old entered U.S. from Liberia 
 Low but not zero risk (training workers, no contact with 
persons with Ebola), monitoring in rural state 
 Temp of 101.1°F, fatigue and myalgia on day 5  
 In the previous week, one family member had fever, 
headache, and vomiting; other family members feeling 
“sick” with cold symptoms 
 Conference call with state HD:  agreed on need to 
evaluate, but some concern about rural hospital 
readiness, media exposure and confidentiality, and actual 
need for admission for these symptoms 
Case study #3 
Management   
 Decision to test for respiratory viruses using rapid test for 
influenza and PCR in state lab 
 Specimen (NP swab) collection performed while PUI in 
car in ER parking lot  
 PUI returned to self-isolation at home 
 ED prescribed oseltamivir for PUI, sick family members, 
and prophylaxis for those not sick in household 
 PUI developed sore throat and cough that evening 
 Advised to take temperature before taking antipyretics 
Case study #3 
Test Results and Outcomes   
 Rapid influenza negative, PCR positive for influenza A 
 24 hours after initiating oseltamivir (3 doses) PUI  
substantially improved, afebrile off anti-pyretics, with 
some residual myalgia, congestion, and cough 
 Family members also improved 
 PUI returned to work two days later 
 State lab PCR machine not used for 24-36 hours until 
clinical improvement assured team that Ebola was not the 
diagnosis. This stoppage necessitated sending some 
specimens for testing to other labs. 
 
 
Take-home points from case studies 
 Appropriate care should be provided in a 
timely manner 
 Media notification can often be managed 
 Consider how and when outpatient 
management may be advantageous  
Why Even Consider Ambulatory 
Evaluation for PUI in the U.S. 
 Low risk of actual Ebola infection 
 ED or inpatient care unnecessary for most common 
travel-related infections 
 Reduce burden on ED and inpatient resources 
 Minimize patient stress and exposure to hospitalization 
risks 
 Minimize public visibility 
Key Parts of a PUI Clinic Visit 
 Triage and scheduling 
 Arrival to clinic 
 Exam room 
 Care team 
 Clinical approach 
 Lab testing 
 Disposition and follow-up 
 Waste management and environmental cleaning 
Triage and Scheduling I 
 Patient referral 
 TravelWell Center (TW) designated as the ambulatory PUI 
evaluation site for Emory 
 Direct referral to TW by public health authorities 
 Criteria for outpatient PUI evaluation (vs. ED or SCDU) 
 Low suspicion for Ebola (unlikely to need Ebola testing) 
 No significant “wet” symptoms (N/V/D/bleeding) 
 No indication for ED or hospitalization 
 PUI can be seen during TW clinic hours without significant delay 
(i.e., weekend PUI triaged to ED) 
Key goals: 
• Stable patients who are unlikely to have Ebola 
(or wet symptoms) triaged to outpatient setting 
• Triage to other settings as appropriate 
Triage and Scheduling II 
 Upon scheduling key parties notified: 
 Public health authorities 
 Infection Control 
 Laboratory 
 Emory Severe Communicable Diseases Unit 
(SCDU) 
 Hospital security, environmental services 
 Neighboring clinics 
 
Key goal:  Keep all stakeholders and potentially 
needed resources informed 
Arrival to TravelWell 
 Instructed to arrive at “back door” for entry via old ambulance 
entrance 
 Arrival team (MD, RN, and security escort) meets PUI in PPE 
 PUI given surgical mask and transported in wheelchair 
 Security escort duties: 
 Clear route, secure elevator 
 Carry clean supplies (emesis bag, towel, etc.), 
communications 
 Avoid contact with PUI 
 Service elevator to TW floor 
 MD and RN of arrival team enter exam room with PUI 
Key goals: 
• Minimize exposure to patients, staff 
• Minimize visibility 
Exam Room 
 Standard exam room with all decorations, 
unnecessary equipment removed or covered 
 Routinely needed equipment set up in room 
 Disposable stethoscopes, BP cuff, penlight, tongue 
depressors, phlebotomy equipment, blood tubes, NP 
swabs, etc. 
 Hand sanitizer 
 Tray to “catch” needed equipment 
 PRN equipment kept outside of room (e.g. bedside 
commode, urinal) 
Key goals: 
• Minimize need for entry/exit 
• Minimize need for passing objects in and out of room 
Staff roles and training   
 Physician* 
 Conducts initial triage 
 Communicates with key internal and external collaborators 
 Examines patient, evaluates 
 Nurse* 
 Transports patient to room 
 Measures VS, assists patient as needed, phlebotomy 
 “Buddy”* (stationed outside room) 
 Monitor for PPE breaches, doffing etc. 
 Transfers supplies into team 
 “Runner” 
 Facilitates communications, obtaining consent, specimen 
drop off, obtaining additional supplies, etc. 
 • *Physician, nurse, and “buddy” are PPE trained 
• Well defined roles and teamwork are key! 
Clinical Approach 
 History and PE 
 Exposure hx, travel dates, etc. 
 Malaria prophylaxis adherence 
 Flu vaccination, sick exposures, etc 
 Aggressive “routine” lab testing 
 Consideration of Ebola testing (non-routine)  
 Strong consideration of empiric treatment 
(oseltamivir, antibiotics, antimalarials etc.) 
Key goals: 
• Do not miss dangerous, treatable infections (malaria, BSI, etc.) 
that may be more likely 
• Confirm alternate diagnosis if possible, or collect evidence 
supporting one…But an alternate diagnosis does not rule out 
Ebola 
• Treat likely cause of illness to facilitate recovery 
Lab testing 
 Phlebotomy and collection in room 
 Standard tests for all febrile PUI 
 CBC/diff, CMP, malaria (RDT/smear), Bcx x 2 
 Consider other tests as indicated 
 NP swab for flu PCR and viral respiratory panel 
 Consider:  Throat swab (rapid strep and cx) 
 UA, urine cx 
 Stool studies 
 Specimens packaged in room, wiped down, dropped 
into transport box outside of room, and transported to 
hospital laboratory 
No routine Ebola testing if low suspicion 
• Turnaround time problematic for PUI in clinic 
• Assays not sensitive during early illness 
*If Ebola testing indicated, all specimens packaged and transported 
under Category A precautions to SCDU laboratory 
Disposition and Follow-up 
 Discharge home if no indication for admission AND 
evaluation determines Ebola as an unlikely diagnosis 
 Consider waiting for STAT test results (malaria RDT, CBC, 
CMP) 
 Home quarantine as per public health authority 
 PUI given 24/7 contact info for TW physician 
 Daily phone follow-up (TW and public health authority) 
 Re-evaluate if symptoms worsen or do not improve as 
expected for an alternative diagnoses 
 Triage to TW, ED, or SCDU as appropriate 
Key goals: 
• Finalize plan with public health authority prior to DC 
• Confirm PUI recovery as would be expected for an alternative diagnosis 
• Pursue further testing (including Ebola) for PUI with persistent 
symptoms consistent with Ebola 
Waste Management and Cleaning 
 If Ebola not suspected 
 All disposable equipment and trash from 
exam into biohazard waste chain 
 Terminal cleaning of room by environmental 
services 
 If Ebola suspected 
 Contact SCDU team for assistance in terminal 
cleaning 
Advance Planning is Critical 
 Engage key stakeholders when developing plan 
 Institutional support is key 
 Practice is critical 
 Drills 
 Tabletop exercises 
 Performance reviews following drills and 
implementations key for process improvement 
Wu HM, Fairley JK, Steinberg J, Kozarsky P. The Potential Ebola–Infected Patient in the Ambulatory Care 
Setting: Preparing for the Worst Without Compromising Care. Ann Intern Med. 2015;162:66-67.  
Ebola Hemorrhagic Fever Website 
For more information please contact Centers for Disease Control and 
Prevention 
1600 Clifton Road NE, Atlanta, GA 30333 
Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 






CME:  The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical  
Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and 
Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim 
credit commensurate with the extent of their participation in the activity.  
 
CNE:  The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the  
American Nurses Credentialing Center's Commission on Accreditation.  This activity provides 1.0 contact hours. 
 
IACET CEU: The CDC has been approved as an Authorized Provider by the International Association for Continuing 
Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to 
offer 0.1 ANSI/IACET CEU's for this program. 
 
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education 
contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program 
is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists 
(MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing 
education contact hours available are 0. CDC provider number GA0082. 
 
CPE:         The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy 
Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 
0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-15-096-L04-P and enduring 0387-0000-15-096-
H04-P. This program is knowledge based. 
 
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.2 hours of continuing 
education in jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE program if you have 





Continuing Education Credit/Contact Hours  




Continuing Education guidelines require that the attendance of all who 
participate in COCA Conference Calls be properly documented. All 
Continuing Education credits/contact hours (CME, CNE, CEU, CECH, 
ACPE and AAVSB/RACE) for COCA Conference Calls/Webinars are 
issued online through the CDC Training & Continuing Education Online 
system (http://www.cdc.gov/TCEOnline/). 
 
Those who participate in the COCA Conference Calls and who wish to 
receive CE credit/contact hours and will complete the online evaluation by 
April 30, 2015 will use the course code WC2286. Those who wish to 
receive CE credits/contact hours and will complete the online evaluation 
between May 1, 2015 and March 31, 2016 will use course code WD2286. 
CE certificates can be printed immediately upon completion of your online 
evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained 
through the CDC Training & Continuing Education Online System will be 




Join Us on 
Facebook 
CDC Facebook page for 
Health Partners! “Like” 
our page today to receive 
COCA updates, 
guidance, and situational 
awareness about 
preparing for and 
responding to public 
health emergencies 
CDC Health Partners Outreach 
http://www.facebook.com/CDCHealthPartnersOutreach 
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